Role of high-risk human papillomavirus in the etiology of oral and oropharyngeal cancers in Thailand: A case–control study

Adit Chotipanich¹, Surattaya Siriarechakul² and On-ong Mungkung³

Abstract

Background: Among developing countries, Thailand shows no increase in the incidence of human papillomavirus–driven oropharyngeal cancer. The causal role of human papillomavirus infection in this pathology has not been researched thoroughly.

Methods: A hospital-based, case–control study was performed which included 104 patients with newly diagnosed oral and oropharyngeal squamous cell carcinomas and 104 individuals without cancer. The Cervista high-risk human papillomavirus and 16/18 assays were used to detect human papillomavirus. Odds ratios were used to assess the association between high-risk genotypes of human papillomavirus and the cancers.

Results: High-risk human papillomavirus was detected in 4 of 52 (7.7%) oral cancer cases, 6 of 52 (11.5%) oropharyngeal cancer cases, and 1 of 104 (0.96%) control subjects. Of 104 cancer patients in the study, 83 were smokers. High-risk human papillomavirus was significantly associated with oropharyngeal cancer (odds ratio = 13.44, 95% confidence interval = 1.6–114.8) but was nonsignificantly associated with oral cancer (odds ratio = 8.58, 95% confidence interval = 0.9–78.9). However, after adjustment for smoking, high-risk human papillomavirus was determined to be nonsignificantly associated with oropharyngeal cancer (adjusted odds ratio = 5.83, 95% confidence interval = 0.8–43.5).

Conclusion: Although low human papillomavirus prevalence was observed, the rate of high-risk human papillomavirus infection in the cancer group was still higher than that in the control group. Smoking may have an influence on the etiology of human papillomavirus–related cancers. However, the study is underpowered to clarify the role of human papillomavirus as the independent risk factor for oral and oropharyngeal cancers in the Thai population.

Keywords

Human papillomavirus, human papillomavirus, smoking, oral cancer, oropharyngeal cancer, prevalence, etiology, Thailand

Date received: 27 March 2017; accepted: 26 February 2018

Introduction

Head and neck cancer is one of the most frequently diagnosed cancers worldwide. The cause of head and neck cancer has been attributed to several factors, including smoking, concurrent smoking and alcohol consumption, betel quid chewing, and virus infections, such as Epstein–Barr virus and human papillomavirus (HPV).¹⁻³ There are more than 100 types of HPV, of which at least 14 are cancer causing (also known as high-risk type). HPV type 16 is the predominant type found in HPV-related head and neck squamous cell cancer.

HPV-related head and neck squamous cell cancer has attracted much attention in recent years. Cumulative evidence shows that HPV infection is one of the significant risk factors for oropharyngeal squamous cell carcinoma; however, the relation between HPV and other head and neck squamous cell cancers remains elusive.⁴

¹ Head and Neck Unit, Chonburi Cancer Hospital, Department of Medical Services, Ministry of Public Health, Chonburi, Thailand
² Head and Neck Unit, Lopburi Cancer Hospital, Department of Medical Services, Ministry of Public Health, Lopburi, Thailand
³ Dentistry Unit, Chonburi Cancer Hospital, Department of Medical Services, Ministry of Public Health, Chonburi, Thailand

Corresponding author:
Adit Chotipanich, Head and Neck Unit, Chonburi Cancer Hospital, Department of Medical Services, Ministry of Public Health, 300 Muang District, Chonburi 20000, Thailand.
Email: oat.adit@gmail.com
A downward trend in smoking and an increased HPV exposure cause an increasing incidence of oropharyngeal squamous cell cancer and a decline of oral squamous cell cancer incidence in many developed countries.²

Despite aggressive anti-smoking campaigns, the incidence rates of oral and oropharyngeal squamous cell cancers in Thailand remained stable for the last decade.³ The factors that contribute to these trends, especially HPV infection, have not been researched thoroughly. Thus, we conducted a study to investigate the role of high-risk HPV (HR-HPV) in oral and oropharyngeal squamous cell cancers in order to understand the actual situation of head and neck squamous cell cancer etiology in Thailand.

Materials and methods

Study design and data collection

This case–control study was conducted at Chonburi and Lopburi cancer hospitals. These hospitals have been assigned as referral centers for cancer patients from 20 provinces in Eastern and Central Thailand. Patients were nonrandomly enrolled. The following inclusion criteria were used: a new diagnosis of oral or oropharyngeal cancer, Thai nationality, and histological features of squamous cell carcinoma. Patients with lip cancers and cancers without clearly demarcated tumor epicenter were excluded. Ethical approval for the study was granted by the respective hospital ethics committees. All study participants provided informed consent prior to their enrollment in this study.

Sample size calculation

The sample requirement for this case–control study was calculated using Epi Info™ version 7.2.1.0 (Division of Health Informatics and Surveillance, Center for Surveillance, Epidemiology and Laboratory Services, Atlanta, GA). The software requires as inputs the estimated HPV infection rates of cases and control subjects. Because no HPV study in Thailand with comparable HPV testing methods was conducted, the assumed HPV infection rates were based from data in other countries. We estimated the presence of HPV infection to be at least 20% in patient cases and less than 2% in control subjects.⁷,⁸ The study was an unmatched design. The control-to-case ratio for each cancer site was 2:1. The desired power to detect a difference was 85% with a 95% confidence interval (CI). Minimum sample size was estimated to be 44 patients and 88 control subjects. Therefore, we aimed to recruit at least 50 oral cancer cases, 50 oropharyngeal cancer cases, and 100 control subjects.

Selection of the control group

The control subjects were recruited from healthy persons and noncancer patients who visited the clinic for a checkup examination. After the enrollment of cancer cases, subjects who matched the case patients by age (±3 years) and sex were invited to participate in the study.

Specimen collection and HPV testing

Epithelial cell samples were collected by primary tumor brushing in the cancer group and normal mouth and throat mucosa brushing in the control group. The brush device was suspended in PreservCyte® transport medium (Hologic, Inc., Marlborough, MA). All specimens were submitted to Chonburi cancer hospital laboratory, and HPV tests were performed within 1 month after collection. The Cervista® HPV assays (Hologic, Inc., Madison, WI) were selected for this study mainly because they were used at that time for gynecologic Papanicolaou tests.

The Cervista assays use the Invader® technology (Hologic, Inc., Madison, WI), a signal amplification method for detection of specific nucleic acid sequences. The Cervista HR-HPV assay detects the presence of 14 HR-HPV types, namely, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. The Cervista HR-HPV assay does not differentiate HPV types; thus, Cervista HPV 16/18 assay was used in conjunction with Cervista HR-HPV assay to assess the presence or absence of HPV types 16 and 18.⁷,⁸ Tests were conducted according to the manufacturer’s guidelines. Inadequate specimens were excluded from the study.

Smoking, alcohol consumption, and betel quid use criteria

Subjects who smoked more than 100 cigarettes in their lives were categorized in the smoking group. Alcohol drinkers were defined as individuals who had consumed at least one drink per week for at least 1 year. Subjects who mentioned the daily frequency of betel quid chewing were categorized in the betel quid use group, regardless of duration.

Statistical analysis

Pearson chi-square or Fisher exact test was used for comparing categorical variables between studied groups. Fisher exact test was used if any expected count in the 2 × 2 table was less than 5. Odds ratios (ORs) were used to assess the association between the cancers and risk factors. Adjusted ORs were calculated by the Cochran–Mantel–Haenszel method, using SPSS 17.0 statistical software (SPSS, Inc., Chicago, IL). A p-value < 0.05 was considered statistically significant.

Results

In total, 104 patients and 104 control subjects were nonrandomly enrolled between January and December 2016. Characteristics of patients with cancer are shown in Table 1.
Smoking was more frequently observed in men. The percentages of smoking were 94.8% in male patients and 37.0% in female patients. All betel quid users in this study were elderly women aged 55–87 years. A total of six (5.8%) patients did not have identifiable risk factors.

The oral squamous cell cancer group comprised 52 patients; 4 (7.7%) patients had positive HR-HPV results revealed by Cervista assay. Subsequent test with Cervista HPV 16/18 assay showed positive results of HPV type 16 in two of these four patients.

The oropharyngeal squamous cell cancer group had 52 patients; 6 (11.5%) patients had positive HR-HPV results revealed by Cervista assay. HPV type 16 was detected in four of these six patients. Only one patient with no history of smoking had a positive result for HPV type 16. Table 2 shows the comparison between HPV-positive and HPV-negative cancers.

The oropharyngeal squamous cell cancer group had 52 patients; 6 (11.5%) patients had positive HR-HPV results revealed by Cervista assay. HPV type 16 was detected in four of these six patients. Only one patient with no history of smoking had a positive result for HPV type 16. Table 2 shows the comparison between HPV-positive and HPV-negative cancers.

Smoking was more frequently observed in men. The percentages of smoking were 94.8% in male patients and 37.0% in female patients. All betel quid users in this study were elderly women aged 55–87 years. A total of six (5.8%) patients did not have identifiable risk factors.

The oral squamous cell cancer group comprised 52 patients; 4 (7.7%) patients had positive HR-HPV results revealed by Cervista assay. Subsequent test with Cervista HPV 16/18 assay showed positive results of HPV type 16 in two of these four patients.

The oropharyngeal squamous cell cancer group had 52 patients; 6 (11.5%) patients had positive HR-HPV results revealed by Cervista assay. HPV type 16 was detected in four of these six patients. Only one patient with no history of smoking had a positive result for HPV type 16. Table 2 shows the comparison between HPV-positive and HPV-negative cancers.

The most common histologic subtypes in the oral and oropharyngeal squamous cell cancer groups were well and moderately differentiated types, respectively. A total of four patients with oropharyngeal squamous cell cancer had a poorly differentiated morphology. Of the four patients with a poorly differentiated morphology, one patient had a positive result for HPV type 16. No basaloid squamous cell cancer was found in this study.

Comparison between the cases and control subjects is shown in Table 3. One control subject was positive for non-16/18 HR-HPV. The case and control subject groups had similar age and sex characteristics.

Table 4 shows the statistical analysis of the association between cancers and risk factors. Smoking was significantly associated with both oral and oropharyngeal squamous cell cancers. Betel quid chewing was significantly associated with oral cancer. HR-HPV was significantly associated with oropharyngeal squamous cell cancer (OR = 13.44, 95% CI = 1.6–114.8) but was nonsignificantly associated with oral squamous cell cancer (OR = 8.58, 95% CI = 0.9–78.9). However, HR-HPV alone, excluding the confounding effect of smoking, was nonsignificantly associated with oropharyngeal squamous cell cancer (adjusted OR = 5.83, 95% CI = 0.8–43.5). Because no control subject was positive for HPV type 16, the calculations of ORs for HPV type 16 were corrected by adding 0.5 to zero values in the contingency tables. HPV type 16 was significantly associated with oropharyngeal squamous cell cancer (OR = 19.39, 95% CI = 1.02–367.4).

Discussion

Background of Thailand

Thailand is located in Southeast Asia and has a population of 65 million. The five most common types of cancer diagnosed
The most common cancer types in Thai people are liver and bile duct, lung, breast, head and neck, and cervical cancer.10

The most common type of head and neck cancer in Thailand is oral cancer. Oropharyngeal cancer is the fourth most common type after oral cancer, nasopharyngeal cancer, and laryngeal cancer. The highest incidence of oral cancer is found in Eastern Thailand. About 4000 Thais are diagnosed with oral and oropharyngeal cancers each year.10,11

Smoking, by far, is the biggest cause of head and neck squamous cell cancer among Thais. Of the five patients, three with oral cancer mentioned tobacco use.11 Since the popularity of betel quid chewing habit has declined, the percentage of oral cancer patients with a history of betel quid chewing decreased from 50.2% to 13.0% in a decade.10,11

The data and statistics on HPV infection and related diseases have been publicized by many researchers around the world. However, little information is available about the correlation between HPV and head and neck squamous cell cancer in Thailand. To the best of our knowledge, this is the first

| Table 2. Comparisons between HR-HPV-positive and HR-HPV-negative cancers. |
|-----------------------------|----------------|----------------|----------------|
| Patients and tumor characteristics | HR-HPV positive | HR-HPV negative | p-value |
| Number of patients | 10 | 94 | – |
| Sex | | | |
| Male | 10 (100%) | 67 (71.3%) | 0.060 |
| Female | 0 (0%) | 27 (28.7%) |  |
| Age (years) | | | |
| 44 | 2 (20%) | 9 (9.6%) | 0.492 |
| 45–65 | 6 (60%) | 54 (57.4%) |  |
| ≥66 | 2 (20%) | 31 (33.0%) |  |
| Oral cavity | | | |
| All | 4 | 48 | 0.522 |
| Oral tongue | 2 | 28 |  |
| Floor of mouth | 1 | 3 |  |
| Palate | 1 | 3 |  |
| Retromolar trigone | 0 | 1 |  |
| Buccal and gum | 0 | 13 |  |
| Oropharynx | | | |
| All | 6 | 46 |  |
| Tonsil | 2 | 21 |  |
| Base of tongue | 1 | 9 |  |
| Other and overlapping sites in oropharynx | 3 | 16 |  |
| Histologic subtypes | | | |
| WD-SCC | 2 (20%) | 53 (56.4%) |  |
| MD-SCC | 7 (70%) | 37 (39.4%) |  |
| PD-SCC | 1 (10%) | 3 (3.2%) |  |
| Bas-SCC | 0 (0%) | 0 (0%) |  |
| SP-SCC | 0 (0%) | 1 (1.1%) |  |
| Smoking | 9 (90%) | 74 (78.7%) | 0.683 |
| Alcohol consumption | 8 (80%) | 67 (71.3%) | 0.722 |
| Betel quid chewing | 0 (0%) | 13 (13.8%) | 0.356 |

HPV: human papillomavirus; HR-HPV: high-risk human papillomavirus; WD: well differentiated; MD: moderately differentiated; PD: poorly differentiated; Bas: basaloid; SP: spindle cell; SCC: squamous cell carcinoma.
A total of four patients (7.7%) in the oral squamous cell cancer group and six patients (11.5%) in the oropharyngeal squamous cell cancer group had positive HPV tests. These prevalence rates were relatively low when compared with the rates found in developed countries. HR-HPV infection prevalence in the oropharyngeal squamous cell cancer group was higher than that in the oral squamous cell cancer group, but the difference was not statistically significant (p = 0.741).

In the normal oral mucosa, previous studies have reported a great variation in HPV rates detected, from 0% all the way to 81.1%. This seems to depend on the population studied, the type of HPV testing, and collection techniques (e.g. brush, swab, rinse, spit, and biopsy). High HPV-positive rates were usually reported by studies with PCR-based techniques.\(^a\) HR-HPV infection rate (0.96%) in the control subjects from this study was comparable to the rate (1.2%) found in the normal mucosa study using similar test and specimen collection techniques.\(^7\)

Sexual behaviors, such as oral sex or oral–anal sex, are strong risk factors for HPV infection in the mouth and throat.\(^19\) The low prevalence rate in this study may reflect cultural characteristics in Thailand that are not conducive to oral HPV transmission. Many Thais conceive that nongenital sexual acts are associated with impurity and immorality.\(^20\) This belief may reduce HPV transmission to the mouth and throat. Furthermore, HPV infection prevalence in the healthy population affects the occurrence of HPV-related diseases. Thailand is one of the countries with a low HPV infection rate. For example, the studies on cervical cancer screening programs of Thai women reported 6.3%–8.2% HR-HPV infection rates.\(^21–23\) However, the US studies reported 21.1%–23.0% infection rates, which were three times higher than the rates in Thailand.\(^24,25\) A recent study has reported that the Asian population exhibits a lower probability of acquiring new HPV infections.\(^26\) The mechanism of how race influences HPV infection is unknown.

Low presence of HPV in the general population and the cultural beliefs in Thailand could contribute to the low prevalence of HPV-related oral and oropharyngeal squamous cell cancers.

### Role of HR-HPV as an etiologic factor

Smoking was the most common risk factor in this study. The percentage of smoking in the oropharyngeal squamous cell cancer group was significantly higher than that in the oral squamous cell cancer group (p < 0.001). Smoking was found to be an independent risk factor for oral and oropharyngeal squamous cell cancers. In contrast to previous studies which reported that HPV-related cancers occur usually in younger ages, the mean ages of the two cancer groups were similar (51.9 years for the oropharyngeal cancer group and 52.7 years for the oral cancer group).

### Table 4. Statistical analysis of the association between cancers and risk factors.

| Factors          | Oral cancer group | Oropharyngeal cancer group |
|------------------|-------------------|---------------------------|
|                  | OR (95% CI)       | p-value | Adjusted OR (95% CI) | p-value | OR (95% CI)       | p-value | Adjusted OR (95% CI) | p-value |
| HR-HPV           | 8.58 (0.9–78.9)   | 0.057   | 4.67\(^a\) (0.5–44.1) | 0.179   | 13.44 (1.6–114.8) | 0.018   | 5.83\(^a\) (0.8–43.5) | 0.086   |
| HPV 16\(^b\)     | 10.35 (0.2–219.6) | 0.134   | –                  | –       | 19.39 (1.02–367.4) | 0.048   | –                  | –       |
| Smoking          | 3.57 (1.8–7.2)    | <0.001  | 4.21\(^c\) (1.9–9.2) | <0.001  | 30.85 (9.0–105.9) | <0.001  | 32.83\(^c\) (8.8–122.6) | <0.001  |
| Alcohol consumption | 3.04 (1.5–6.1)  | 0.002   | 1.90\(^a\) (0.8–4.3) | 0.126   | 11.32 (4.8–26.7) | <0.001  | 4.02\(^a\) (1.5–11.0) | 0.007   |
| Betel quid chewing | 4.90 (1.7–14.0)  | 0.003   | 6.25\(^a\) (2.1–18.6) | 0.001   | 0.32 (0.04–2.7)  | 0.298   | 0.31\(^a\) (0.03–3.5) | 0.342   |

OR: odds ratio; CI: confidence interval; HPV: human papillomavirus; HR-HPV: high-risk human papillomavirus.

\(^a\)ORs were adjusted for smoking.

\(^b\)Zero values in contingency tables were corrected by adding 0.5.

\(^c\)ORs were adjusted for HR-HPV and betel quid chewing.
and nonsmoking male patients, in this study, HR-HPV infection was more common among male smokers. This can be caused by a higher proportion of smoking patients. In addition, no significant difference in age was observed between HPV-positive and HPV-negative cancers (p = 0.492).

Studies performed in various countries have suggested that HR-HPV is an independent risk factor for oral and oropharyngeal squamous cell cancers. Similarly, our study found a significant association between HR-HPV and oropharyngeal squamous cell cancer, but it was underpowered to reach a conclusion about the relationship between HR-HPV and oral squamous cell cancer. Moreover, the ORs for HR-HPV associated with both cancers, after adjustment for smoking, were considerably lower than the crude ORs. This suggested that smoking was a strong confounder of the association between HR-HPV and oral and oropharyngeal squamous cell cancers. However, unadjusted and adjusted ORs for HR-HPV associated with the cancers need to be interpreted with caution. The precision of these results was limited by a wide CI. The stratified analysis was not accurate due to many subgroups in the stratification contained few or no subjects enrolled. Thus, further larger studies are necessary in order that the role of HPV as the independent risk factor for oral and oropharyngeal squamous cell cancers in the Thai population can be clarified.

**Strengths and limitations of the study**

This study used the Food and Drug Administration (FDA) approved, commercially available HPV test, unlike most prior HPV studies which used in-house assays. The Cervista assays have proven intra- and inter-laboratory reproducibility. The presence of an internal control in the Cervista assays reduces the possibility of false-negative results due to insufficient DNA present. Specimens were newly collected to avoid errors from contamination and deterioration.

The main limitation in this study is insufficient sample size, especially in the control group, making an underpowered statistic. In fact, the number of samples in this study was fairly comparable with those in other studies, and sample size requirement was calculated with a valid method. Much lower than expected HPV prevalence found in this study was likely to be the cause of this limitation. As mentioned in the “Materials and methods” section, due to lack of suitable data relating to HPV prevalence in the study population, the sample size requirement was calculated based on available data in other countries. Based on the HPV infection rate found in this study, the sample size needs to be doubled in order to reach an acceptable level of statistical power. Moreover, in order to avoid having no case or no control in a stratum, we may need to increase the sample size to three or four times of its original size so that the stratified analysis can yield a reliable result. These required numbers for sample size are too high to reasonably achieve within the study setting for this investigation.

There were other factors that might affect the credibility of the low HPV infection results found in this study. Initially, the study did not use the traditional HPV testing modalities, such as p16 immunohistochemistry screening followed by in situ hybridization or DNA PCR-based techniques. Although the Cervista assays have been used by others for head and neck tumor material testing, the assays still do not have regulatory approval for use outside the setting of the detection of cervical HPV DNA. In addition, nonrandom sampling method used in this study might create selection bias.

**Conclusion**

The study investigated the role of HR-HPV in the etiology of oral and oropharyngeal squamous cell cancers in a developing country with no increase in the incidence of HPV-driven oropharyngeal squamous cell cancer. The prevalence rates of HR-HPV infection in oral and oropharyngeal squamous cell cancers were relatively low when compared with the rates in other developed countries. Smoking may have an influence on the etiology of HPV-related cancers. So far, the study can merely point out that HR-HPV plays a lesser role than other well-established risk factors, such as smoking and betel chewing. Although the study is underpowered to clarify the role of HPV as the independent risk factor for oral and oropharyngeal squamous cell cancers in the Thai population, it adds to the very few studies done in Thailand. Results from this study provided an approximate sample size needed for future studies in Thailand and other countries with a similar epidemiologic trend. Due to low prevalence of HPV, the potential benefit of HPV vaccine on the occurrence of head and neck squamous cell cancer in Thais is still in question. Smoking prevention remains the most important strategy to control these cancers.

**Acknowledgements**

We would like to thank Ms Anong Krachang, Mr Kittipong Mannmatt, and laboratory staff at Chonburi cancer hospital for support in HPV testing. Additionally, we would like to thank Dr Sombat Wongmanee (MD), Dr Orapin Chokchaitam (DDS), and Dr Jarumon Sirapracha (DDS) for their support in sample collection. We are grateful to Dr Suthat Duangdeeden, the director of Chonburi cancer hospital, for his support and encouragement. S. Siriarechakul and A. Chotipanich were responsible for the conception of the study, the acquisition, and analysis of data. O. Mungkung and A. Chotipanich were responsible for the enrollment and matching of the control group. A. Chotipanich was responsible for drafting and revising. All authors have approved the final article.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethical approval**

Ethical approval for this study was obtained from the hospital ethics committee (approval number: 13/2015).
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent
Written informed consent was obtained from all subjects before the study.

ORCID iD
Adit Chotipanich https://orcid.org/0000-0002-3180-930X

References
1. Radoî L, Menvielle G, Cyr D, et al. Population attributable risks of oral cavity cancer to behavioral and medical risk factors in France: results of a large population-based case–control study, the ICARE study. BMC Cancer 2015; 15: 827.
2. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Betel-quid and areca-nut chewing and some areca-nut derived nitrosamines. IARC Monogr Eval Carcinog Risks Hum 2004; 85: 1–334.
3. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24–35.
4. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142–4148.
5. Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonopharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region. Head Neck 2013; 35: 747–755.
6. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013; 31: 4550–4559.
7. González-Losa M, del R, Manzano-Cabrera L, et al. Low prevalence of high risk human papillomavirus in normal oral mucosa by hybrid capture 2. Braz J Microbiol 2008; 39(1): 32–34.
8. Hooper JE, Hebert JF, Schilling A, et al. Hybrid capture 2 is as effective as PCR testing for high-risk human papillomavirus in head and neck cancers. Appl Immunohistochem Mol Morphol 2015; 23: 266–272.
9. Vermorken JB, Pysrri A, Mesria R, et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol 2014; 25: 801–807.
10. Komolmala N, Chuachamsai S, Tantiwiwawin S, et al. Ten-year analysis of oral cancer focusing on young people in northern Thailand. J Oral Sci 2015; 57: 327–334.
11. Iamaroon A, Pattanaponkorn R, Pongsirisriwet S, et al. Analysis of 587 cases of oral squamous cell carcinoma in northern Thailand with a focus on young people. Int J Oral Maxillofac Surg 2004; 33: 84–88.
12. Boscolo-rizzo P, Del Mistro A, Bussu F, et al. New insights into human papillomavirus-associated head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital 2013; 33: 77–87.
13. Goodman MT, Saraiya M, Thompson TD, et al. Human papillomavirus genotype and oropharynx cancer survival in the United States of America. Eur J Cancer 2015; 51: 2759–2767.
14. Blumberg J, Monjane L, Prasad M, et al. Investigation of the presence of HPV related oropharyngeal and oral tongue squamous cell carcinoma in Mozambique. Cancer Epidemiol 2015; 39: 1000–1005.
15. Chen XJ, Sun K and Jiang WW. Absence of high-risk HPV 16 and 18 in Chinese patients with oral squamous cell carcinoma and oral potentially malignant disorders. Virol J 2016; 13: 81.
16. Hauck F, Oliveira-Silva M, Dreyer JH, et al. Prevalence of HPV infection in head and neck carcinomas shows geographical variability: a comparative study from Brazil and Germany. Virchows Arch 2015; 466: 685–693.
17. Chattopadhyay K. A comprehensive review on host genetic susceptibility to human papillomavirus infection and progression to cervical cancer. Indian J Hum Genet 2011; 17: 132–144.
18. Castro TP and Bussoloti Filho I. Prevalence of human papillomavirus (HPV) in oral cavity and oropharynx. Braz J Otorhinolaringo 2006; 72: 272–282.
19. Rettig E, Kiess AP and Fakhry C. The role of sexual behavior in head and neck cancer: implications for prevention and therapy. Expert Rev Anticancer Ther 2015; 15: 35–49.
20. Taywaditep KJ, Coleman E and Dumronggittigule P. Thailand. In: Francoeur RT and Noonan RJ (eds) The continuum complete international encyclopedia of sexuality. New York: Continuum International Publishing Group, 2004, pp. 1021–1053, http://doi.org/10.1093/acref/9780199754700.001.0001.
21. Kantathavorn N, Mahidol C, Sritana N, et al. Genotypic distribution of human papillomavirus (HPV) and cervical cytology findings in 5906 Thai women undergoing cervical cancer screening programs. Infect Agent Cancer 2015; 10: 7.
22. Sukvirach S, Smith JS, Tunsakul S, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand, J Infect Dis 2003; 187: 1246–1256.
23. Swangvaree SS, Kongkaew P, Rugsuj P, et al. Prevalence of high-risk human papillomavirus infection and cytologic results in Thailand. Asian Pac J Cancer Prev 2016; 17: 1465–1468.
24. Howe ER, Li Z, McGlennen RC, et al. Type-specific prevalence and persistence of human papillomavirus in women in the United States who are referred for typing as a component of cervical cancer screening. Am J Obstet Gynecol 2009; 200: 245e1–245e7.
25. Dickson EL, Vogel RI, Bliss RL, et al. Multiple-type HPV infections: a cross-sectional analysis of the prevalence of specific types in 309,000 women referred for HPV testing at the time of cervical cytology. Int J Gynecol Cancer 2013; 23: 1295–1302.
26. Schabath MB, Villa LL, Lin HY, et al. Racial differences in the incidence and clearance of human papilloma virus (HPV): the HPV in men (HIM) study. Cancer Epid Biomar Prev 2013; 22: 1762–1770.
27. D’Souza G, Kreimer AR, Viscidi R, et al. Case–control study of human papillomavirus and oropharyngeal cancer. *N Engl J Med* 2007; 356: 1955–1956.

28. Chaitanya NC, Allam NS, Gandhi Babu DB, et al. Systematic meta-analysis on association of human papilloma virus and oral cancer. *J Cancer Res Ther* 2016; 12: 969–974.

29. Boers A, Wang R, Slagter-Menkema L, et al. Clinical validation of the Cervista HPV HR test according to the international guidelines for human papillomavirus test requirements for cervical cancer screening. *J Clin Microbiol* 2014; 52: 4391–4393.

30. Nasher AT, Al-Hebshi NN, Al-Moayad EE, et al. Viral infection and oral habits as risk factors for oral squamous cell carcinoma in Yemen: a case-control study. *Oral Surg Oral Med Oral Pa* 2014; 118: 566–572.

31. Elango KJ, Suresh A, Erode EM, et al. Role of human papilloma virus in oral tongue squamous cell carcinoma. *Asian Pac J Cancer Prev* 2011; 12: 889–896.

32. Toman J, Von Larson S, Umeno H, et al. HPV-positive oropharyngeal cancer via p16 immunohistochemistry in Japan. *Ann Oto Rhinol Laryn* 2017; 126: 152–158.